Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Thomas

Showing results (281-290 of 300) with videos related to

Pageof 30
Sort By:
Cancer Cell|January 20, 2023
Base editing screens map mutations affecting interferon-γ signaling in cancerMatthew A Coelho, Sarah Cooper, Magdalena E Strauss, et al.
The New Zealand Medical Journal|June 30, 2020
Medical considerations for supporting elite athletes during the post-peak phase of the New Zealand COVID-19 pandemic: a New Zealand sporting code consensusBruce Hamilton, Lynley Anderson, Nat Anglem, et al.
Nature Communications|January 10, 2026
Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extensionPeter Nordbeck, Ozlem Goker-Alpan, John A Bernat, et al.
Nature Communications|August 29, 2020
Refinement of pore size at sub-angstrom precision in robust metal-organic frameworks for separation of xylenesXiaolin Li, Juehua Wang, Nannan Bai, et al.
Nature Genetics|July 5, 2024
Saturation genome editing of BAP1 functionally classifies somatic and germline variantsAndrew J Waters, Timothy Brendler-Spaeth, Danielle Smith, et al.
BMJ Open|October 11, 2020
Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiativeDerralynn A Hughes, Patricio Aguiar, Patrick B Deegan, et al.
Genome Research|September 8, 2012
The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expressionThomas Derrien, Rory Johnson, Giovanni Bussotti, et al.
JMIR Public Health and Surveillance|December 19, 2022
Representativeness, Vaccination Uptake, and COVID-19 Clinical Outcomes 2020-2021 in the UK Oxford-Royal College of General Practitioners Research and Surveillance Network: Cohort Profile SummaryMeredith Leston, William H Elson, Conall Watson, et al.
JMIR Public Health and Surveillance|June 3, 2020
The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: Protocol to Develop Extended COVID-19 Surveillance and Trial PlatformsSimon de Lusignan, Nicholas Jones, Jienchi Dorward, et al.
Journal of Medical Genetics|November 12, 2016
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT studyDerralynn A Hughes, Kathleen Nicholls, Suma P Shankar, et al.
Pageof 30

Showing results (281-290 of 300) with videos related to

Sort By:
Pageof 30
Cancer Cell|January 20, 2023
Base editing screens map mutations affecting interferon-γ signaling in cancerMatthew A Coelho, Sarah Cooper, Magdalena E Strauss, et al.
The New Zealand Medical Journal|June 30, 2020
Medical considerations for supporting elite athletes during the post-peak phase of the New Zealand COVID-19 pandemic: a New Zealand sporting code consensusBruce Hamilton, Lynley Anderson, Nat Anglem, et al.
Nature Communications|January 10, 2026
Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extensionPeter Nordbeck, Ozlem Goker-Alpan, John A Bernat, et al.
Nature Communications|August 29, 2020
Refinement of pore size at sub-angstrom precision in robust metal-organic frameworks for separation of xylenesXiaolin Li, Juehua Wang, Nannan Bai, et al.
Nature Genetics|July 5, 2024
Saturation genome editing of BAP1 functionally classifies somatic and germline variantsAndrew J Waters, Timothy Brendler-Spaeth, Danielle Smith, et al.
BMJ Open|October 11, 2020
Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiativeDerralynn A Hughes, Patricio Aguiar, Patrick B Deegan, et al.
Genome Research|September 8, 2012
The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expressionThomas Derrien, Rory Johnson, Giovanni Bussotti, et al.
JMIR Public Health and Surveillance|December 19, 2022
Representativeness, Vaccination Uptake, and COVID-19 Clinical Outcomes 2020-2021 in the UK Oxford-Royal College of General Practitioners Research and Surveillance Network: Cohort Profile SummaryMeredith Leston, William H Elson, Conall Watson, et al.
JMIR Public Health and Surveillance|June 3, 2020
The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: Protocol to Develop Extended COVID-19 Surveillance and Trial PlatformsSimon de Lusignan, Nicholas Jones, Jienchi Dorward, et al.
Journal of Medical Genetics|November 12, 2016
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT studyDerralynn A Hughes, Kathleen Nicholls, Suma P Shankar, et al.
Pageof 30